Company profile: QurAlis
1.1 - Company Overview
Company description
- Provider of precision medicines for ALS and FTD, including therapeutic candidates QRL-201 to restore STMN2 expression and QRL-101 to reduce hyperexcitability-induced neurodegeneration by opening Kv7 channels, and platforms: QR43 to discover precision therapies for TDP-43-related diseases and FlexASO to develop antisense oligonucleotides that modulate RNA splicing.
Products and services
- FlexASO Platform: Architects ASO-based therapeutics that modulate RNA splicing to treat ALS and FTD, producing antisense oligonucleotides designed for precise RNA processing control
- QRL-101: Engineers an ion channel–targeted therapeutic that opens Kv7 channels to lower hyperexcitability and thereby reduce neurodegeneration in ALS patients
- QRL-201: Constructs a gene expression–targeted therapeutic candidate aimed at restoring STMN2 expression in ALS patients, with a focus on specific STMN2 expression recovery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to QurAlis
Eagle Genomics
HQ: United Kingdom
Website
- Description: Provider of enterprise software enabling management, orchestration and exploitation of genomics and other life sciences data. Solutions include e[datascientist] for multi-omics data and metadata; Network Life Sciences Platform leveraging network science, AI and hypergraphs; Valuation and Decision Engine for prioritizing entity relationships; cloud-based Analysis Hub; Catalog with governance; and a Multi-layer Hypergraph tool.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eagle Genomics company profile →
Arbor Biotechnologies
HQ: United States
Website
- Description: Provider of next-generation gene editing therapeutics and tools to create targeted genetic medicines for liver and CNS diseases, supported by an AI/ML-powered discovery engine for high-throughput screening. Develops lipid nanoparticle-delivered liver therapies, AAV-delivered CNS therapies, and partners on ex vivo cell-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arbor Biotechnologies company profile →
enGene
HQ: Canada
Website
- Description: Provider of biotechnological treatments for mucosal diseases by inducing therapeutic proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full enGene company profile →
Adverum Biotechnologies
HQ: United States
Website
- Description: Provider of gene therapy, developing medicines with therapeutic benefits. Offerings include Ixo-vec, a gene therapy product candidate for wet age-related macular degeneration designed for single administration, and the OPTIC clinical program investigating the safety, efficacy, and long-term outcomes of Ixo-vec in wet AMD patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adverum Biotechnologies company profile →
GeneTether
HQ: United States
Website
- Description: Provider of genome editing enhancement platforms that tether or conjugate donor DNA templates to editing complexes, including the GeneTether Platform and TNT technology to boost DNA insertion efficiency with targeted tools like CRISPR-Cas, and pursuing strategic partnerships in human therapeutics, animal health, agriculture, and cell delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneTether company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for QurAlis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to QurAlis
2.2 - Growth funds investing in similar companies to QurAlis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for QurAlis
4.2 - Public trading comparable groups for QurAlis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →